This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
June 13, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook GSK’s vaccine leverages GMMA technology. GSK has licensed altSonflex1-2-3, its Shigella vaccine candidate, to Bharat Biotech for continued development and distribution in low and middle-income nations. Credit: viewimage/Shutterstock.
The Department of Health – Abu Dhabi (DoH) and Sanofi have signed a memorandum of understanding (MoU) to bolster vaccine development by leveraging local health-tech ecosystems and research infrastructure. Credit: Department of Health Abu Dhabi.
Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial (..)
Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial (..)
mRNA vaccine coverage on Pharmaceutical Technology (or Clinical Trials Arena) is supported by Trilink. By partnering with Ethris, we are expanding our services to include cutting-edge mRNA manufacturing, empowering our customers to bring life-changing treatments to patients faster and more efficiently.”
How will RFK Jr’s American dream for vaccines play out? Syngene’s expertise in the field is covered in this whitepaper. Syngene’s expertise in the field is covered in this whitepaper. You will receive an email shortly. Please check your inbox to download the Whitepaper. You will receive an email shortly.
Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial (..)
How will RFK Jr’s American dream for vaccines play out? Sectors Sections Clinical Trials Drug Manufacturers Therapy Area Pricing and Market Access Latest E.
For instance, reminders about flu vaccines during peak season can boost patient engagement. High-quality blog posts, whitepapers, and case studies can boost your visibility. Use Personalized Communication One-size-fits-all is no longer effective.
How will RFK Jr’s American dream for vaccines play out? of equity shares from JB employees at the same price per share as offered to KKR. of equity shares from JB employees at the same price per share as offered to KKR.
How will RFK Jr’s American dream for vaccines play out? Sectors Sections Clinical Trials Drug Manufacturers Therapy Area Pricing and Market Access Latest E.
July 24, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The companies aim to gain insights that could contribute information towards designing more vaccines. We are excited to combine our expertise with Sanofi’s leadership in vaccine development to advance next-generation therapeutics and vaccines.”
By GlobalData Learn more about Strategic Intelligence FDA’s strategy on trial designs, vaccines and manufacturing Earlier this month, when the Department of Health and Human Sciences Secretary Robert Kennedy Jr.
How will RFK Jr’s American dream for vaccines play out? Sectors Sections Clinical Trials Drug Manufacturers Therapy Area Pricing and Market Access Latest E.
Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial (..)
July 23, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The acquisition includes vaccine candidates for respiratory syncytial virus and human metapneumovirus. These fully liquid vaccines can be provided in prefilled syringes, improving safety, ease of use and operational efficiency in healthcare settings.
How will RFK Jr’s American dream for vaccines play out? Sectors Sections Clinical Trials Drug Manufacturers Therapy Area Pricing and Market Access Latest EC approves BeOne’s Tevimbra for nasopharyngeal carcinoma Formulate Faster.
Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial (..)
How will RFK Jr’s American dream for vaccines play out? Sectors Sections Clinical Trials Drug Manufacturers Therapy Area Pricing and Market Access Latest E.
Find out more The transaction will see BioNTech assimilate its former rival in the Covid-19 vaccine arena. By GlobalData Learn more about Strategic Intelligence In July 2024, CureVac streamlined its focus towards oncology after selling influenza and Covid-19 vaccine development to GSK in a deal worth nearly €1.5bn.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content